NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $30.36 -0.41 (-1.33%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$30.12▼$30.9650-Day Range$20.96▼$30.7752-Week Range$14.56▼$31.00Volume865,661 shsAverage Volume1.13 million shsMarket Capitalization$4.35 billionP/E RatioN/ADividend YieldN/APrice Target$38.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside26.3% Upside$38.33 Price TargetShort InterestBearish7.57% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.51Based on 8 Articles This WeekInsider TradingSelling Shares$663,600 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.54) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector252nd out of 927 stocksBiological Products, Except Diagnostic Industry37th out of 154 stocks 4.4 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.57% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 7.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 1.9 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $663,600.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.54) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -31.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -31.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...Click here to discover how Wall Street insiders are quietly preparing for a market crash >>> About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesSeptember 16 at 1:45 AM | americanbankingnews.comFY2025 EPS Estimates for Denali Therapeutics Inc. (NASDAQ:DNLI) Cut by AnalystSeptember 11, 2024 | americanbankingnews.comDenali Therapeutics (NASDAQ:DNLI) Rating Reiterated by Cantor FitzgeraldSeptember 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…September 10, 2024 | americanbankingnews.comAnalysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.33September 7, 2024 | americanbankingnews.comFY2025 Earnings Forecast for Denali Therapeutics Inc. Issued By Leerink Partnrs (NASDAQ:DNLI)September 6, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI)September 4, 2024 | markets.businessinsider.comDenali Therapeutics: Strong Buy on Regulatory Wins and ETV Franchise ProgressSeptember 4, 2024 | bizjournals.comDenali looks to scale new heights in quest for treatment for rare genetic disorderSeptember 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…September 3, 2024 | msn.comDenali to file for FDA accelerated approval of DNL310 in early 2025September 3, 2024 | markets.businessinsider.comDenali Therapeutics’ DNL310 Shows Promise for Early Approval and Market SuccessSeptember 3, 2024 | globenewswire.comDenali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)August 26, 2024 | finance.yahoo.comDenali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three yearsAugust 25, 2024 | ca.finance.yahoo.comDenali Therapeutics Inc (4DN.BE)August 24, 2024 | ca.finance.yahoo.comDNLI Sep 2024 22.500 putAugust 21, 2024 | seekingalpha.comDenali Therapeutics Continues To Have Plenty Of Moving PartsAugust 15, 2024 | investing.comDenali Therapeutics Inc (DNLI)August 14, 2024 | globenewswire.comDenali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous AdministrationSee More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/16/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees364Year Founded2015Price Target and Rating Average Stock Price Target$38.33 High Stock Price Target$90.00 Low Stock Price Target$22.00 Potential Upside/Downside+25.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net MarginsN/A Pretax Margin-33,119.50% Return on Equity-33.63% Return on Assets-30.66% Debt Debt-to-Equity RatioN/A Current Ratio12.46 Quick Ratio12.46 Sales & Book Value Annual Sales$330.53 million Price / Sales13.24 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book4.12Miscellaneous Outstanding Shares143,160,000Free Float131,343,000Market Cap$4.38 billion OptionableOptionable Beta1.37 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $802.29kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsCytokineticsNASDAQ:CYTKProthenaNASDAQ:PRTAREGENXBIONASDAQ:RGNXVaxcyteNASDAQ:PCVXNeurocrine BiosciencesNASDAQ:NBIXView All CompetitorsInsiders & InstitutionsDana Investment Advisors Inc.Bought 5,513 shares on 8/27/2024Ownership: 0.024%Creative PlanningBought 3,458 shares on 8/16/2024Ownership: 0.030%Algert Global LLCSold 55,345 shares on 8/16/2024Ownership: 0.019%Quarry LPSold 500 shares on 8/16/2024Ownership: 0.005%Point72 Asia Singapore Pte. Ltd.Bought 8,335 shares on 8/15/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $21.46 at the beginning of 2024. Since then, DNLI stock has increased by 41.5% and is now trading at $30.36. View the best growth stocks for 2024 here. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) announced its quarterly earnings data on Thursday, August, 1st. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09. The firm's revenue was down 99.7% on a year-over-year basis. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' top institutional shareholders include Baillie Gifford & Co. (9.65%), Marshall Wace LLP (1.70%), Bank of New York Mellon Corp (1.08%) and Dimensional Fund Advisors LP (0.99%). Insiders that own company stock include Marc Tessier-Lavigne, Alexander O Schuth, Ryan J Watts, Carole Ho, Vicki L Sato and Steve E Krognes. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP) and Anavex Life Sciences (AVXL). This page (NASDAQ:DNLI) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts